Clinical impact of C-reactive protein to albumin ratio of the 7th postoperative day on prognosis after laparoscopic colorectal cancer surgery

Masahiro Kataoka, Kuniyuki Gomi, Ken Ichioka, Takuya Iguchi, Tomoki Shirota, Arano Makino, Ko Shimada, Kiyotomi Maruyama, Motohiro Mihara, Shoji Kajikawa

Department of Surgery, Suwa Red Cross Hospital, Nagano, Japan

**Purpose**
To determine the relationship between perioperative C-reactive protein to albumin ratio (CAR) and the prognosis of colorectal cancer patients.

**Methods**
Systemic inflammation in colorectal cancer

Stage 0 to III CRC patients
May 2011 to December 2016 (n=320)

Biomarker
- NLR
- mGPS
- PNI
- CAR

**Result**
Survival according to the CAR on POD 7

Before propensity score matching

After propensity score matching

**Conclusion**
The high CAR at POD 7 was related to the significantly worse RFS and OS after laparoscopic colorectal cancer surgery.
Purpose: C-reactive protein to albumin ratio (CAR) has been utilized as a prognostic factor in various carcinomas. We investigated the relationship between preoperative, postoperative day (POD) 1, and POD 7 CARs and the prognosis of patients with colorectal cancer (CRC).

Methods: Three hundred twenty patients with CRC who underwent laparoscopic radical resection between May 2011 and December 2016 were enrolled. Patients were selected into 2 groups, high CAR and low CAR (72 patients per group), based on preoperative, POD 1, and POD 7 CARs. The relapse-free survival (RFS) and overall survival (OS) were compared between groups using propensity score matching.

Results: The high CAR group had a significantly worse RFS (P < 0.001) and OS (P = 0.002) at POD 7 than those in the low CAR group. However, in preoperative and POD 1 analysis, no differences were observed.

Conclusion: In patients with CRC, CAR of POD 7 was a significant prognostic factor.

Keywords: C-reactive protein; Albumins; Colorectal neoplasms; Laparoscopy; Prognosis

INTRODUCTION

Colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer-related death worldwide [1]. It is therefore essential to investigate the prognostic factors of CRC.

The influence of systemic inflammation in various carcinomas has been widely reported in recent years [2, 3]. In addition, multiple biomarkers of systemic inflammation have been developed, including the prognostic nutritional index (PNI) [4], the neutrophil to lymphocyte ratio (NLR) [5], and the modified Glasgow Prognostic Score (mGPS) [6], all of which have been reported to be related to CRC prognosis. While mGPS uses C-reactive protein (CRP) and albumin levels, CRP to albumin ratio (CAR) is a calculated value developed by Fairclough et al. [7].

CAR has been reported to be useful in predicting disease outcomes such as sepsis [8], acute pancreatitis [9], and ulcerative colitis [10]. Furthermore, it has been reported to be a useful biomarker in various carcinomas, including gastric cancer [11], esophageal cancer [12], pancreatic cancer [13], gallbladder carcinoma [14], and ovarian cancer [15]. Both CRP and albumin, factors used in CAR, are synthesized in the liver. Chronic systemic inflammation induced by cancer cells increases CRP synthesis and decreases albumin synthesis in the liver. These 2 factors are indirect measures of systemic inflammation, metabolic abnormalities, and cachexia [16].

CAR has been associated with CRC prognosis [17, 18]. However, the impact of perioperative CAR on the prognosis of CRC after surgery has not been thoroughly investigated. The purpose of this study is to evaluate the influence of preoperative and postoperative CAR on relapse-free survival (RFS) rates and overall survival (OS) rates for CRC patients who underwent radical resection.

METHODS

Chart reviews were conducted retrospectively on 362 patients with CRC who underwent laparoscopic resection at Suwa Red Cross Hospital (Nagano, Japan) from May 2011 to December 2016. Patients with metastasis, residual tumor, recurrent CRC, or synchronous malignancy were excluded. A total of 320 patients were included in the analysis. Informed consent was obtained from the patients for this study, and the study protocol was approved by the Ethics Committee of Suwa Red Cross Hospital (No. 3-22).

Clinical variables, such as age, sex, the American Society of Anesthesiologists (ASA) physical status (PS) classification, preoperative carcinoembryonic antigen (CEA) level, preoperative carbohydrate antigen (CA19-9) level, tumor information (location, size, histotype, presence of lymphatic or venous invasion, and stage classification), and postoperative complications (grade II or higher on the Clavien-Dindo classification) were obtained from patient records. The resected CRC was staged using the TNM classification system of the 8th edition of the Union for International Cancer Control. The survival rate, recurrence status, and time to recurrence were also investigated. RFS rate and OS rate were used to evaluate them. RFS was defined as the period of time from the start of treatment that patients were alive with no evidence of cancer recurrence, while OS was defined as the period of time patients were alive from the start of treatment, regardless of the cause of death. Serum CRP and albumin levels at preoperative, the 1st postoperative day (POD 1), and the 7th postoperative day (POD 7) were analyzed, and CAR was calculated by dividing the CRP level (mg/dL) by the albumin level (g/L).

We used EZR software (R Foundation for Statistical Computing) for statistical processing. The cutoff values for each CAR at preoperative, POD 1, and POD 7 were determined by analyzing the receiver operating characteristic (ROC) curves for survival.
rate. Patients were divided into 2 groups based on the cutoff value: the high CAR and low CAR groups. In addition, propensity score matching was used to minimize any potential confounding bias between the 2 groups that might affect prognosis. We performed a 1:1 matching without replacement through the nearest available matching, with the caliper set at 0.2. Each patient was propensity scored, based on a logistic regression model addressing the following 11 variables: age, sex, ASA PS classification, serum CEA level, serum CA19-9 level, tumor location, tumor size, tumor histotype, lymphatic invasion, venous invasion, and TNM stage. The chi-square or Fisher exact tests tested differences in categorical variables, and survival rates (5-year RFS rate and 5-year OS rate) were analyzed using the Kaplan-Meier method. The P-values of < 0.05 were considered significant.

In addition, the multivariable Cox proportional hazard model was used to determine the hazard ratios (HRs) and 95% confidence intervals (CIs) for CAR of POD 7 for recurrence and survival, adjusting for age, sex, ASA PS classification, serum CEA level, serum CA19-9 level, tumor location, tumor size, tumor histotype, lymphatic invasion, venous invasion, and TNM stage.

RESULTS

Data from 320 patients with stage 0 to III CRC were collected for this study. With 5-year OS as the endpoint, the optimal cutoff value for CAR was determined using the area under the curve (AUC) of the ROC curve. The preoperative cutoff value was 0.038 (AUC, 0.666), the cutoff value on POD 1 was 2.007 (AUC, 0.649), and the cutoff value on POD 7 was 0.859 (AUC, 0.632).

Analysis of preoperative CAR

First, we reviewed preoperative CAR. Before propensity score matching, there were 144 patients in the high CAR group (CAR ≥ 0.038) and 176 patients in the low CAR group (CAR < 0.038). Patients in the high CAR group were older than those in the low CAR group (73.82 ± 10.79 years vs. 68.62 ± 11.83 years, P < 0.001) and had a higher proportion of males (59.7% vs. 46.0%, P = 0.018).

In addition, the high CAR group (vs. low CAR group) showed significant differences in ASA PS classification (P < 0.001), preoperative CEA (≥ 5 ng/mL; 48.6% vs. 30.1%, P = 0.001), tumor size (≥ 50 mm; 47.2% vs. 15.3%, P < 0.001), lymphatic invasion (54.9% vs. 40.9%, P = 0.014), venous invasion (51.4% vs. 33.0%, P = 0.001), and pathological stage (P < 0.001). The 2 groups were then propensity score matched in a 1:1 ratio (93 patients per group), and there were no differences between groups (Table 1). There was no significant difference in postoperative complications either before or after propensity score matching.

Before propensity score matching, the 5-year RFS was 66.4% in the high CAR group compared to 82.7% in the low CAR group (P < 0.001). Also, 5-year OS was 74.5% in the high CAR group and 89.5% in the low CAR group (P < 0.001) (Fig. 1A, B). After propensity score matching, the results showed that 5-year RFS was 73.3% in the high CAR group and 76.1% in the low CAR group (P = 0.784). The 5-year OS was 83.0% in the high CAR group and 85.7% in the low CAR group (P = 0.669) (Fig. 1C, D).

Analysis of CAR on POD 1

Second, we reviewed CAR of POD 1. Before propensity score matching, there were 95 patients in the high CAR group (CAR ≥ 2.007) and 225 patients in the low CAR group (CAR < 2.007). The high CAR group (vs. low CAR group) showed significant differences in age (74.0 ± 11.2 years vs. 69.7 ± 11.6 years, P = 0.002), ASA PS classification (P < 0.001), preoperative CEA (≥ 5 ng/mL; 51.6% vs. 32.9%, P = 0.002), tumor size (≥ 50 mm; 43.2% vs. 24.0%, P = 0.001), lymphatic invasion (60.0% vs. 41.8%, P = 0.003), venous invasion (52.6% vs. 36.4%, P = 0.009), and pathologic stage (P = 0.026). Next, the 2 groups were propensity score matched in a 1:1 ratio (81 patients per group), but no differences were observed between groups (Table 2). For postoperative complications, there was a significant difference even after propensity score matching.

Before propensity score matching, the 5-year RFS was 62.7% in the high CAR group and 80.5% in the low CAR group (P < 0.001). Five-year OS was 68.4% in the high CAR group and 88.5% in the low CAR group (P < 0.001) (Fig. 2A, B). After propensity score matching, 5-year RFS was 66.6% in the high CAR group and 71.5% in the low CAR group (P = 0.220). Five-year OS was 70.1% in the high CAR group and 83.4% in the low CAR group (P = 0.059) (Fig. 2C, D).

Analysis of CAR on POD 7

Finally, we reviewed the CAR of POD 7. Before propensity score matching, there were 75 patients in the high CAR group (CAR ≥ 0.859) and 245 patients in the low CAR group (CAR < 0.859). The high CAR group (vs. low CAR group) was older (74.32 ± 9.64 years vs. 69.94 ± 12.02 years, P = 0.004), consisted of a higher proportion of males (69.3% vs. 46.9%, P = 0.001), and showed significant differences in any of the measured variables (P < 0.001). Also, 5-year OS was 74.5% in the high CAR group compared to 82.7% in the low CAR group (P < 0.001). Five-year OS was 70.1% in the high CAR group and 83.4% in the low CAR group (P = 0.059) (Fig. 2C, D).
Table 1. Clinicopathological parameters of CRC patients with respect to preoperative CAR

| Variable                      | Before PSM | After PSM |
|-------------------------------|------------|-----------|
|                               | High CAR (≥ 0.038) | Low CAR (< 0.038) | P-value | High CAR (≥ 0.038) | Low CAR (< 0.038) | P-value |
| No. of patients               | 144        | 176       | 93      | 93                 |
| Sex                           |            |           |         |                    |                    |
| Male                          | 86 (59.7)  | 81 (46.0) | 0.018   | 53 (57.0)          | 53 (57.0)          | > 0.999 |
| Female                        | 58 (40.3)  | 95 (54.0) |         | 40 (43.0)          | 40 (43.0)          |         |
| Age (yr)                      | 73.8 ± 10.8| 68.6 ± 11.8| < 0.001 | 71.9 ± 11.8        | 71.4 ± 10.5        | 0.738   |
| ASA PS classification         |            |           |         |                    |                    |
| I                             | 7 (4.9)    | 25 (14.2) |         | 7 (7.5)            | 2 (2.2)            |         |
| II                            | 87 (60.4)  | 124 (70.5)|         | 58 (62.4)          | 69 (74.2)          |         |
| III                           | 49 (34.0)  | 27 (15.3) |         | 27 (29.0)          | 22 (23.7)          |         |
| IV                            | 1 (0.7)    | 0 (0)     | < 0.001 | 1 (1.1)            | 0 (0)              | 0.114   |
| CEA (ng/mL)                   |            |           |         |                    |                    |
| ≤ 5                           | 74 (51.4)  | 123 (69.9)| < 0.001 | 51 (54.8)          | 55 (59.1)          |         |
| > 5                           | 70 (48.6)  | 53 (30.1) | 0.001   | 42 (45.2)          | 38 (40.9)          | 0.657   |
| CA19-9 (U/mL)                 |            |           |         |                    |                    |
| ≤ 35                          | 114 (79.2) | 152 (86.4)| 0.100   | 76 (81.7)          | 74 (79.6)          | 0.853   |
| > 35                          | 30 (20.8)  | 24 (13.6) |         | 17 (18.3)          | 19 (20.4)          |         |
| Tumor location                |            |           |         |                    |                    |
| Right-side                    | 52 (36.1)  | 73 (45.1) |         | 34 (36.6)          | 34 (36.6)          |         |
| Left-side                     | 92 (63.9)  | 103 (58.5)| 0.358   | 59 (63.4)          | 59 (63.4)          | > 0.999 |
| Tumor size (mm)               |            |           |         |                    |                    |
| ≤ 50                          | 76 (52.8)  | 149 (84.7)| < 0.001 | 69 (74.2)          | 68 (73.1)          | > 0.999 |
| > 50                          | 68 (47.2)  | 27 (15.3) | 0.014   | 24 (25.8)          | 25 (26.9)          | > 0.999 |
| Tumor histotype               |            |           |         |                    |                    |
| pap/tub                       | 133 (92.4) | 170 (96.6)| 0.132   | 89 (95.7)          | 87 (93.5)          | 0.747   |
| muc/por/sig                   | 11 (7.6)   | 6 (3.4)   |         | 4 (4.3)            | 6 (6.5)            |         |
| Lymphatic invasion            |            |           |         |                    |                    |
| No                            | 65 (45.1)  | 104 (59.1)| 0.014   | 50 (53.8)          | 47 (50.5)          | 0.769   |
| Yes                           | 79 (54.9)  | 72 (40.9) |         | 43 (46.2)          | 46 (49.5)          |         |
| Venous invasion               |            |           |         |                    |                    |
| No                            | 70 (48.6)  | 118 (67.0)| 0.001   | 53 (57.0)          | 54 (58.1)          | > 0.999 |
| Yes                           | 74 (51.4)  | 58 (33.0) | 0.001   | 40 (43.0)          | 39 (41.9)          |         |
| Pathological stage            |            |           |         |                    |                    |
| 0                             | 5 (3.5)    | 29 (16.5) |         | 5 (5.4)            | 7 (7.5)            |         |
| I                             | 24 (16.7)  | 56 (31.8) |         | 24 (25.8)          | 23 (24.7)          |         |
| II                            | 68 (47.2)  | 45 (25.6) |         | 35 (37.6)          | 30 (32.3)          |         |
| III                           | 47 (32.6)  | 46 (26.1) | < 0.001 | 29 (31.2)          | 33 (35.5)          | 0.805   |
| Postoperative complication*   | 13 (9.0)   | 12 (6.8)  | 0.533   | 7 (7.5)            | 9 (9.7)            | 0.795   |

Values are presented as number only, number (%), or mean ± standard deviation.
CRC, colorectal cancer; CAR, C-reactive protein to albumin ratio; PSM, propensity score matching; ASA PS, American Society of Anesthesiologists physical status; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; pap, papillary; tub, tubular; muc, mucinous; por, poorly differentiated; sig, signet-ring cell.

Five-year OS was 63.8% in the high CAR group and 88.1% in the low CAR group (P < 0.001) (Fig. 3A, B). After propensity score matching, 5-year RFS was 49.6% in the high CAR group and 79.6% in the low CAR group (P < 0.001). Five-year OS was 64.0% in the high CAR group and 84.6% in the low CAR group (P = 0.002) (Fig. 3C, D).

Out of the 144 patients selected by propensity score matching from POD 7 results, an additional comparison was made between patients with postoperative complications (19 patients) and patients without postoperative complications (125 patients). The 5-year RFS was 65.2% for patients with postoperative complications and 65.0% for patients without postoperative complications (P = 0.989). Five-year OS was 72.4% in patients with postoperative complications and 75.0% in patients without postoperative complications.

Kataoka M, et al.
The results showed that the presence of postoperative complications did not affect survival rate.

As shown above, before propensity score matching, all CARs of preoperative, POD 1, and POD 7 were associated with prognosis. However, after propensity score matching and background equalization, only the CAR of POD 7 was found to have a significant relationship with the prognosis of CRC patients.

Finally, a multivariable Cox proportional hazard model was used to analyze the CAR of POD 7. In the model, the HR for recurrence was 2.69 (95% CI, 1.70–4.26) for POD 7 with higher CAR (P < 0.001). For survival, the HR for survival was 2.72 (95% CI, 1.60–4.63) for POD 7 with higher CAR (P < 0.001). Thus, in this analysis, CAR of POD 7 was still an independent predictor of recurrence and survival, even after adjusting for each variable.

**DISCUSSION**

Various studies have shown that biomarkers such as PNI and NLR, which reflect systemic inflammation, are prognostic factors for malignancy [4, 5]. The mGPS, derived from serum albumin and CRP levels, is among these biomarkers and is predictive of prognosis in CRC patients [6]. CAR, which is calculated from the ratio of serum albumin to CRP, has also been used as a prognostic marker. Both albumin and CRP in serum are proteins synthesized in the liver. In the presence of inflammation, CRP synthesis is stimulated by inflammatory cytokines, while albumin synthesis is suppressed [19]. CAR therefore sensitively detects systemic inflammation, and preoperative CAR has been reported to have prognostic utility in gastric cancer [20], esophageal cancer [21], and gallbladder carcinoma [14].
| Variable                      | Before PSM |          |          | After PSM |          |          |
|-------------------------------|------------|----------|----------|-----------|----------|----------|
|                               | High CAR   | Low CAR  | P-value  | High CAR  | Low CAR  | P-value  |
| No. of patients               | 95         | 225      |          | 81        | 81       |          |
| Sex                           |            |          |          |           |          |          |
| Male                          | 45 (47.4)  | 122 (54.2) | 0.273 | 43 (53.1) | 43 (53.1) | >0.999   |
| Female                        | 50 (52.6)  | 103 (45.8)|          | 38 (46.9) | 38 (46.9) |          |
| Age (yr)                      | 74.0 ± 11.2 | 69.7 ± 11.6 | 0.002 | 72.4 ± 11.1 | 73.5 ± 10.4 | 0.511   |
| ASA PS classification         |            |          |          |           |          |          |
| I                             | 7 (7.4)    | 25 (11.1) |          | 7 (8.6)   | 7 (8.6)  |          |
| II                            | 50 (52.6)  | 161 (71.6) | 0.002 | 45 (55.6) | 48 (59.3) |          |
| III                           | 38 (40.0)  | 38 (16.9) |          | 29 (35.8) | 25 (30.9) |          |
| IV                            | 0 (0)      | 1 (0.4)  | <0.001   | 0 (0)     | 1 (1.2)  | 0.813    |
| CEA (ng/mL)                   |            |          |          |           |          |          |
| ≤ 5                           | 46 (48.4)  | 151 (67.1) |          | 44 (54.3) | 48 (59.3) |          |
| > 5                           | 49 (51.6)  | 74 (32.9) | 0.002    | 37 (45.7) | 33 (40.7) | 0.634    |
| CA19-9 (U/mL)                 |            |          |          |           |          |          |
| ≤ 35                          | 74 (77.9)  | 192 (85.3) |          | 65 (80.2) | 66 (81.5) |          |
| > 35                          | 21 (22.1)  | 33 (14.7) | 0.141    | 16 (19.8) | 15 (18.5) | >0.999   |
| Tumor location                |            |          |          |           |          |          |
| Right-side                    | 43 (45.3)  | 82 (36.4) |          | 33 (40.7) | 28 (34.6) |          |
| Left-side                     | 52 (54.7)  | 143 (63.6) | 0.168   | 48 (59.3) | 53 (65.4) | 0.517    |
| Tumor size (mm)               |            |          |          |           |          |          |
| ≤ 50                          | 54 (56.8)  | 171 (76.0) |          | 51 (63.0) | 49 (60.5) |          |
| > 50                          | 41 (43.2)  | 54 (24.0) | 0.001    | 30 (37.0) | 32 (39.5) | 0.872    |
| Tumor histotype               |            |          |          |           |          |          |
| pap/tub                       | 86 (90.5)  | 217 (96.4) |          | 76 (93.8) | 76 (93.8) |          |
| muc/por/sig                   | 9 (9.5)    | 8 (3.6)  | 0.052    | 5 (6.2)   | 5 (6.2)  | >0.999   |
| Lymphatic invasion            |            |          |          |           |          |          |
| No                            | 38 (40.0)  | 131 (58.2) |          | 36 (44.4) | 32 (39.5) |          |
| Yes                           | 57 (60.0)  | 94 (41.8) | 0.003    | 45 (55.6) | 49 (60.5) | 0.633    |
| Venous invasion               |            |          |          |           |          |          |
| No                            | 45 (47.4)  | 143 (63.6) |          | 41 (50.6) | 39 (48.1) |          |
| Yes                           | 50 (52.6)  | 82 (36.4) | 0.009    | 40 (49.4) | 42 (51.9) | 0.875    |
| Pathological stage            |            |          |          |           |          |          |
| 0                             | 9 (9.5)    | 25 (11.1) |          | 9 (11.1)  | 4 (4.9)  |          |
| I                             | 16 (16.8)  | 64 (28.4) |          | 16 (19.8) | 16 (19.8) |          |
| II                            | 32 (33.7)  | 81 (36.0) |          | 22 (27.2) | 37 (45.7) |          |
| III                           | 38 (40.0)  | 55 (24.4) | 0.026    | 34 (42.0) | 24 (29.6) | 0.060    |
| Postoperative complication*   | 13 (13.7)  | 12 (5.3)  | 0.020    | 11 (13.6) | 2 (2.5)  | 0.009    |

Values are presented as number only, number (%), or mean ± standard deviation.
CRC, colorectal cancer; CAR, C-reactive protein to albumin ratio; PSM, propensity score matching; ASA PS, American Society of Anesthesiologists physical status; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; pap, papillary; tub, tubular; muc, mucinous; por, poorly differentiated; sig, signet-ring cell.
*Clavien-Dindo grade > II.

In this study, there was no clear interrelationship between preoperative and POD 1 CAR and prognosis after propensity score matching. In contrast, CAR of POD 7 showed a strong relationship with prognosis even after propensity score matching and was regarded as an independent factor. Although it is not clear why these results were obtained, several factors may be involved.

It is conceivable that one of the factors explaining the temporal difference in the relationship between CAR and perioperative timing may be postoperative complications. It has been previously reported that postoperative complications in CRC surgery are associated with a poorer prognosis [22]. Complications within the first week after surgery may cause a prolonged inflammatory response reflected in the CAR of POD 7. In reality, however, the analysis showed that postoperative complications were not related.
to prognosis in this case group, and the effect was not significant. Therefore, other factors may have been present.

One possible factor is that CAR reflects the postoperative systemic inflammation caused by the residual tumor cells. Malignant tumors are known to produce inflammatory cytokines [23]. It has been reported that the local immune response and systemic inflammation caused by malignant tumors affect the survival rate of cancer patients [2]. Residual cancer cells may prolong the postoperative inflammatory response, resulting in a poor prognosis for patients. However, it is unclear how microscopic cancer cells in patients who have undergone curative resection will affect the body, and it is questionable whether they can cause a prolonged inflammatory state.

On the other hand, there is a report that surgical stress and postoperative acute phase reactants may promote tumor survival and growth after tumor resection [23]. It has also been reported that surgical stress increases the expression of E-selectin in vascular endothelial cells, which in turn may increase postoperative hematogenous metastasis [24]. According to these reports, the inflammation itself worsens the prognosis by creating an environment more conducive to cancer metastasis and growth. The impact of high invasiveness of surgery on the prognosis of patients cannot be denied, and reducing the invasiveness may improve the prognosis of patients.

The impact of high levels of inflammatory markers on POD 7 on recurrence of malignancy has been reported elsewhere. Hayama et al. [25] reported that the NLR of POD 7 was a significant predictor of reduced RFS in stage II postoperative CRC patients.
Table 3. Clinicopathological parameters of CRC patients with respect to CAR at the 7th postoperative day

| Variable                        | Before PSM | After PSM | P-value | Before PSM | After PSM | P-value |
|---------------------------------|------------|-----------|---------|------------|-----------|---------|
| No. of patients                 |            |           |         |            |           |         |
| Sex                             |            |           |         |            |           |         |
| Male                            | 75 (69.3)  | 245       |         | 72 (68.1)  | 54 (75.0) |         |
| Female                          | 23 (30.7)  | 130 (53.1)| 0.001  | 23 (31.9)  | 18 (25.0) | 0.460  |
| Age (yr)                        | 74.3 ± 9.6 | 69.9 ± 12.0| 0.004  | 74.2 ± 9.7 | 73.4 ± 9.2| 0.635  |
| ASA PS classification           |            |           |         |            |           |         |
| I                               | 2 (2.7)    | 30 (12.2) | 0.004  | 2 (2.8)    | 1 (1.4)  |         |
| II                              | 41 (54.7)  | 170 (69.4)|         | 41 (56.9)  | 42 (58.3)|         |
| III                             | 31 (41.3)  | 45 (18.4) |         | 29 (40.3)  | 29 (40.3)|         |
| IV                              | 1 (1.3)    | 0 (0.0)   | <0.001 | 0 (0.0)    | 0 (0.0)  | >0.999 |
| CEA (ng/mL)                     |            |           |         |            |           |         |
| ≤ 5                             | 43 (57.3)  | 154 (62.9)|         | 41 (56.9)  | 39 (54.2)|         |
| > 5                             | 32 (42.7)  | 91 (37.1) | 0.417  | 31 (43.1)  | 33 (45.8)| 0.867  |
| CA19-9 (U/mL)                   |            |           |         |            |           |         |
| ≤ 35                            | 64 (85.3)  | 202 (82.4)|         | 61 (84.7)  | 56 (77.8)|         |
| > 35                            | 11 (14.7)  | 43 (17.6) | 0.725  | 11 (15.3)  | 16 (22.2)| 0.393  |
| Tumor location                  |            |           |         |            |           |         |
| Right-side                      | 29 (38.7)  | 96 (39.2) |         | 28 (38.9)  | 28 (38.9)|         |
| Left-side                       | 46 (61.3)  | 149 (60.8)| >0.999 | 44 (61.1)  | 44 (61.1)| >0.999 |
| Tumor size (mm)                 |            |           |         |            |           |         |
| ≤ 50                            | 48 (64.0)  | 177 (72.2)|         | 46 (63.9)  | 49 (68.1)|         |
| > 50                            | 27 (36.0)  | 68 (27.8) | 0.194  | 26 (36.1)  | 23 (31.9)| 0.725  |
| Tumor histotype                 |            |           |         |            |           |         |
| pap/tub                         | 71 (94.7)  | 232 (94.7)|         | 68 (94.4)  | 69 (95.8)|         |
| muc/por/sig                     | 4 (5.3)    | 13 (5.3)  | >0.999 | 4 (5.6)    | 3 (4.2)  | >0.999 |
| Lymphatic invasion              |            |           |         |            |           |         |
| No                              | 35 (46.7)  | 134 (54.7)|         | 33 (45.8)  | 37 (51.4)|         |
| Yes                             | 40 (53.3)  | 111 (45.3)| 0.236  | 39 (54.2)  | 35 (48.6)| 0.617  |
| Venous invasion                 |            |           |         |            |           |         |
| No                              | 40 (53.3)  | 148 (60.4)|         | 38 (52.8)  | 45 (62.5)|         |
| Yes                             | 35 (46.7)  | 97 (39.6) | 0.286  | 34 (47.2)  | 27 (37.5)| 0.312  |
| Pathological stage              |            |           |         |            |           |         |
| 0                               | 6 (8.0)    | 28 (11.4) |         | 6 (8.3)    | 8 (11.1)|         |
| I                               | 14 (18.7)  | 66 (26.9) |         | 13 (18.1)  | 19 (26.4)|         |
| II                              | 32 (41.7)  | 81 (33.1) |         | 30 (41.7)  | 23 (31.9)|         |
| III                             | 23 (30.7)  | 70 (28.6) | 0.297  | 23 (31.9)  | 22 (30.6)| 0.510  |
| Postoperative complication*     | 17 (23.3)  | 8 (3.3)   | <0.001 | 16 (22.9)  | 3 (4.2)  | 0.001  |

Values are presented as number only, number (%), or mean ± standard deviation.
CRC, colorectal cancer; CAR, C-reactive protein to albumin ratio; PSM, propensity score matching; ASA, American Society of Anesthesiologists; PS, physical status; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; pap, papillary; tub, tubular; muc, mucinous; por, poorly differentiated; sig, signet-ring cell.
*Clavien-Dindo grade > II.

In esophageal cancer, Ibuki et al. [26] reported that RFS was significantly reduces when CRP levels were high on POD 7. As shown in these studies and the present study, postoperative inflammation is associated with recurrence and prognosis, and therefore, merits further investigation.

Our study has several limitations. First, this is a retrospective, single-center study. Although propensity score matching has been performed, the possibility of random error, selection bias, and confounding cannot be ruled out. A multicenter, prospective study would strengthen the level of evidence. Second, there is no consensus cutoff value for CAR, which makes it difficult to apply clinically at this point. In this study, we used the ROC curve to determine the cutoff values for each day, but it may be necessary to calculate these values in a more extensive study. Finally, it is un-
Fig. 3. Analysis for C-reactive protein to albumin ratio (CAR) of the 7th postoperative day. Relapse-free survival (RFS) and overall survival (OS) rates prior to propensity score matching (A, B) and after propensity score matching (C, D).

![Graphs showing RFS and OS rates](A: CAR < 0.859 vs CAR ≥ 0.859, P < 0.001; B: CAR < 0.859 vs CAR ≥ 0.859, P < 0.001)

Fig. 4. Comparison of relapse-free survival (A) and overall survival (B) rates in patients who were propensity score matched and selected by CAR of the 7th postoperative day and grouped according to the presence or absence of postoperative complication.

![Graphs showing RFS and OS rates](A: CAR < 0.859 vs CAR ≥ 0.859, P = 0.964; B: CAR < 0.859 vs CAR ≥ 0.859, P = 0.989)

https://doi.org/10.3393/ac.2022.00234.0033
clear whether any intervention in patients with high POD 7 CAR would improve their prognosis. Further research is needed to address this critical point.

In conclusion, the results of propensity score matching showed that CAR on POD 7 was an independent prognostic factor for RFS and OS in patients with CRC after radical resection; however, no relationship was found for preoperative or POD 1 CAR. Patients with high CAR on POD 7 may require adjuvant chemotherapy and more careful management.

ARTICLE INFORMATION

Conflict of interest
No potential conflict of interest relevant to this article was reported.

Funding
None.

Author contributions
Conceptualization: MK, KG; Data curation: MK; Formal analysis: all authors; Visualization: MK; Writing–original draft: MK; Writing–review & editing: all authors. All authors read and approved the final manuscript.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
2. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol 2014;15:e493–503.
3. Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol 2013;33 Suppl 1:S79–84.
4. Luvián-Morales J, González-Trejo S, Carrillo JE; Herrera-Goeppfert R, Aiello-Crocifoglio V, Gallardo-Rincón D, et al. Association of the prognostic nutritional index and overall survival in patients with colorectal cancer: a STROBE compliant retrospective cohort study. Cancer Med 2019;8:3379–88.
5. Haram A, Boland MR, Kelly ME, Bolger JC, Waldron RM, Kerin MJ. The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review. J Surg Oncol 2017;115:470–9.
6. Numata K, Ono Y, Toda S, Kamioka Y, Suematsu H, Sawazaki S, et al. Modified Glasgow Prognostic Score and carcinoembryonic antigen predict poor prognosis in elderly patients with colorectal cancer. Oncol Res Treat 2020;43:125–33.
7. Fairclough E, Cairns E, Hamilton J, Kelly C. Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein/albumin ratio as a predictor of patient outcome. Clin Med (Lond) 2009;9:30–3.
8. Ranzani OT, Zampieri FG, Forte DN, Azevedo LC, Park M. C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. PloS One 2013;8:e59321.
9. Kaplan M, Ates I, Akpinar MY, Yüksel M, Kuzu UB, Kacar S, et al. Predictive value of C-reactive protein/albumin ratio in acute pancreatitis. Hepatobiliary Pancreat Dis Int 2017;16:424–30.
10. Sayar S, Kurbuz K, Kahraman R, Caliskan Z, Atalay R, Ozturk O, et al. A practical marker to determining acute severe ulcerative colitis: CRP/albumin ratio. North Clin Istamb 2019;7:49–55.
11. Yue L, Lu Y, Li Y, Wang Y. Prognostic value of C-reactive protein to albumin ratio in gastric cancer: a meta-analysis. Nutr Cancer 2021;73:1864–71.
12. Tamagawa H, Aoyama T, Tamagawa A, Komori K, Maenza Y, Kano K, et al. Influence of the preoperative C-reactive protein-to-albumin ratio on survival and recurrence in patients with esophageal carcinoma. Anticancer Res 2020;40:2365–71.
13. Vujic J, Marsoner K, Winerorrother V, Mischinger HJ, Kornprat P. The predictive value of the CRP-to-albumin ratio for patients with pancreatic cancer after curative resection: a retrospective single center study. In Vivo 2019;33:2071–8.
14. Utsumi M, Aoki H, Nagahisa S, Nishimura S, Une Y, Kimura Y, et al. Preoperative C-reactive protein/albumin ratio as a predictive factor for gallbladder carcinoma. In Vivo 2020;34:1901–8.
15. Liu Y, Chen S, Zheng C, Ding M, Zhang L, Wang L, et al. The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer. BMC Cancer 2017;17:285.
16. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009;12:223–6.
17. Shibutani M, Maeda K, Nagahara H, Iseki Y, Ikeya T, Hirakawa K. Prognostic significance of the preoperative ratio of C-reactive protein to albumin in patients with colorectal cancer. Anticancer Res 2016;36:995–1001.
18. Shibutani M, Maeda K, Nagahara H, Iseki Y, Hirakawa K, Ohira M. The significance of the C-reactive protein to albumin ratio as a marker for predicting survival and monitoring chemotherapeutic effectiveness in patients with unresectable metastatic colorectal cancer. Springerplus 2016;5:1798.
19. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448–54.
20. Toiyama Y, Shimura T, Yasuda H, Fujikawa H, Okita Y, Kobayashi M, et al. Clinical burden of C-reactive protein/albumin...
ratio before curative surgery for patients with gastric cancer. Anticancer Res 2016;36:6491–8.

21. Ishibashi Y, Tsujimoto H, Hiraki S, Kumano I, Yaguchi Y, Horiguchi H, et al. Prognostic value of preoperative systemic immunoinflammatory measures in patients with esophageal cancer. Ann Surg Oncol 2018;25:3288–99.

22. Arnarson Ö, Butt-Tuna S, Syk I. Postoperative complications following colonic resection for cancer are associated with impaired long-term survival. Colorectal Dis 2019;21:805–15.

23. Miki C, Konishi N, Ojima E, Hatada T, Inoue Y, Kusunoki M. C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma. Dig Dis Sci 2004;49:970–6.

24. Hagi T, Kurokawa Y, Kobayashi N, Takahashi T, Saito T, Yamashita K, et al. Anti-metastatic effect of methylprednisolone targeting vascular endothelial cells under surgical stress. Sci Rep 2021;11:6268.

25. Hayama T, Hashiguchi Y, Okada Y, Ono K, Nemoto K, Shimada R, et al. Significance of the 7th postoperative day neutrophil-to-lymphocyte ratio in colorectal cancer. Int J Colorectal Dis 2020;35:119–24.

26. Ibuki Y, Hamai Y, Hihara J, Emi M, Taomoto J, Furukawa T, et al. Role of postoperative C-reactive protein levels in predicting prognosis after surgical treatment of esophageal cancer. World J Surg 2017;41:1558–65.